A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

Overview of attention for article published in Cancer Immunology, Immunotherapy, January 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 58 Dimensions

Readers on

mendeley: 94 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS

Application WO-2019213510-A1

World Intellectual Property Organisation (WIPO)